Clinical Pharmacology Adaptive Therapy Group
Professor Banerji's group aims to study re-wiring of signal transduction to understand and overcome mechanisms of drug resistance and, in addition, to understand exploit cancer evolution using pharmacological tools.
We are focused on the re-wiring of signal transduction using established cell lines to control mechanisms of drug resistance and comprehend the evolution of cancer.
Rewiring of signal transduction
This group is working on the set-up and validation of a highly sensitive antibody-based assay on the Nanostring platform which will allow quantification of 50 - 100 phosphoproteins/proteins. It plans to digest tumour tissue obtained during surgery or from biopsies and expose them to a matrix of 20 - 30 anticancer drugs before obtaining phosphoproteomic data.
It also aims to use organoids and patient-derived xenografts to take this forward. The proteomic data will be modelled with the Computational Biology and Chemogenomics Team led by Professor Bissan Al-Lazikani. The group also supports PhD students studying the re-wiring of signal transduction in colon cancer and the role of stroma in influencing signal transduction.
The group also currently works with Professor Andrea Sottoriva at the Centre for Evolution and Cancer at the ICR to look at barcoding of cancer cells and the study of evolutionary trajectories of clones under experimental conditions. It is also studying mechanisms of resistance, collateral drug sensitivity and resistance of these emergent clones.
The primary area of this group is focused on the re-wiring of signal transduction using established cell lines as well as fresh cancer cells derived and isolated from patients and then exposing them to novel anticancer drugs. Pre- and post-proteomic profiling provides insights into mechanisms of drug resistance and how to overcome this with combination therapies. The initial work was carried out using cancer cells isolated from ascites and pleural effusions; the group in now developing expertise in organoid and patient-derived xenograft tissue.
The group develops its own antibody-based proteomic platforms and collaborates with teams involved in mass spectroscopic methods, led by Jyoti Choudhary. The group generates significant amounts of data and collaborates with the ICR's Computational Biology and Chemogenomics Team led by Professor Bissan Al-Lazikani to develop and decipher the data.
The secondary focus of this lab is the study of the pharmacological effects on cancer evolution in experimental models and methods to quantify this and herd cancer cells to a vulnerable state.
Professor Banerji works with Professor Andrea Sottoriva in the Centre for Evolution and Cancer at the ICR and plans to translate these concepts in to the clinic.
Vacancies at the ICR
Working at the ICR
Senior Technician - in vivo biology
About you The ICR is one of the world's leading cancer research institutes, aiming to defeat cancer. As a Senior Laboratory Technician you will contribute directly to this mission by supporting vital in vivo research. We are looking for a highly motivated, detail-oriented individual, committed to high-quality work. Key requirements include: Education and Knowledge BSc in Life Sciences or IAT Level 3 (Essential) Home Office Personal Licence (PILA, B, C) or equivalent (Essential) Understanding of tumour biology and pre-clinical models (Desirable) Skills Skilled in dissection, surgery, dosing of agents and sampling techniques (Essential) Strong organisational, communication and interpersonal skills (Essential) Ability to work independently and in a team with other scientists and BSU staff (Essential) Computer proficiency and willingness to pursue professional development (Essential) Experience Proven experience in in vivo oncology and PDX models (Essential) Strong foundation in animal (rodent) husbandry and behaviour (Essential) Experience in stereotaxic surgery, imaging techniques and sample preparation (Desirable) What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension Department/Directorate Information We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Bishani Wickrama via email on: [email protected].
Business Development Manager
About the Role We are seeking a Business Development Manager to join The Institute of Cancer Research’s (ICR’s) Business and Innovation Office and contribute to to support a portfolio of academics by protecting and commercialising their research, supporting them in securing translational funding and to highlight to them the benefits of working with industry. The successful candidate will play a key role in strategic project evaluation, stakeholder engagement, IP protection, commercial deal-making (collaborations and licensing), and translational funding support. Key Responsibilities Identify and assess commercially viable research Protect IP and manage confidentiality agreements Draft and negotiate licensing and collaboration contracts Support translational funding applications Drive spinout opportunity management About You We are looking for a proactive, detail-oriented team player. PhD, MBA or equivalent in a relevant field Experience in business development or technology transfer Direct experience of negotiating and closing deals with external partners Strong communication, negotiation, and organizational skills What We Offer • Supportive, collaborative environment • Career development opportunities • Competitive salary and pension Department/Directorate Information The Business and Innovation Office drives commercialisation and strategic partnerships to maximise patient benefit. For more details, please refer to the job pack. For an informal discussion regarding the role, please contact Dr. Amritha Nair via Email on [email protected]
Employee Story
Dr Fatemeh Ahmadi Moughari is a bioinformatician working in the Functional Genomics Team, led by Rachael Natrajan, and the Bioinformatics Team, led by Syed Haider. She joined the ICR from her home country of Iran where she completed her PhD in anti-cancer drug response at Shahid Beheshti University.
"I really enjoy the multidisciplinary atmosphere here and it’s the thing that stood out when I first joined the ICR."
Industrial partnership opportunities with this group
Opportunity: A potent, orally bioavailable clinical-stage inhibitor of MPS1 with potential as a treatment for a range of cancer types including triple negative breast cancer
Commissioner: Swen Hoelder
